NCT03567187View on ClinicalTrials.gov

Cryoneurolysis for Improvements in Pain, ADL and QOL in Patients With Ankle Osteoarthritis

NACompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

July 3, 2018

Primary Completion Date

January 28, 2021

Study Completion Date

January 28, 2021

Conditions
Ankle Osteoarthritis
Interventions
DEVICE

iovera

The iovera° device is 510(k)-cleared (K133453 and K161835) and is used to form a precisely controlled, sub-dermal cold zone of -20 to -88.5 degrees Celsius to temporarily disrupt peripheral nerve function, ultimately blocking pain. It is not indicated for the treatment of central nervous system tissue.

Trial Locations (1)

66160

University of Kansas Medical Center, Kansas City

All Listed Sponsors
lead

University of Kansas Medical Center

OTHER

NCT03567187 - Cryoneurolysis for Improvements in Pain, ADL and QOL in Patients With Ankle Osteoarthritis | Biotech Hunter | Biotech Hunter